Ingevity Corporation NGVT
73.00
1.21
1.69%
as of 25 Sep
- Market cap
- $2.5B
- P/E
- 47.4×
Follow NGVT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 48.49 |
P/S ratio |
1.91 | 1.84 | 2.13 | 2.23 | |
P/FCF ratio |
8.36 | 7.74 | 10.22 | 16.72 | |
P/Operating CF |
15.45 | 22.08 | (1,255.68) | (187.70) | |
P/B ratio |
14.51 | 72.18 | 64.56 | 55.23 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.96 | 2.78 | 2.92 | 3.00 | |
EV/EBITDA |
6.27 | 13.19 | 13.66 | 14.65 | |
EV/Operating CF |
10.38 | 9.81 | 11.30 | 16.51 | |
EV/FCF |
12.94 | 11.72 | 13.97 | 22.49 | |
Quick Ratio |
0.61 | 0.60 | 0.81 | 1.00 | |
Current Ratio |
1.27 | 1.33 | 1.42 | 1.61 | |
Net Debt/EBITDA |
9.79 | (23.97) | 9.89 | 10.63 | |
Debt/Assets |
63.17% | 70.34% | 65.59% | 68.70% | |
Debt/Equity |
8.39 | 39.10 | 27.83 | 22.52 | |
Asset Turnover |
0.52 | 0.64 | 0.64 | 0.68 | |
Operating CF/Net income |
2.98 | (1.15) | (0.03) | (0.39) | |
Capex/Depreciation |
(0.55) | (0.72) | (0.45) | (0.47) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2.10% | 2.90% | 2.60% | 1.94% | |
Selling, General and Administrative Expense of Revenue |
13.24% | 16.31% | 15.78% | 12.42% | |
Intangible Assets out of Total Assets |
0.15 | 0.11 | 0.10 | 0.09 | |
Share Based Compensation of Revenue |
1.59% | 1.76% | 1.86% | 1.34% | |
Graham Net Nets |
(0.59) | (0.54) | (0.41) | (0.37) | |
Graham Number |
0.00 | 0.00 | 0.00 | 6.84 | |
Earnings Yield |
(3.26%) | (7.82%) | (4.91%) | 2.06% | |
Free Cash Flow Yield |
11.96% | 12.93% | 9.79% | 5.98% | |
Revenue per Share |
9.17 | 7.04 | 7.32 | 9.05 | |
Operating CF per Share |
3.57 | 2.68 | (0.06) | (0.40) | |
Capex per Share |
(0.43) | (0.55) | (0.29) | (0.30) | |
Free Cash Flow per Share |
3.15 | 2.13 | (0.35) | (0.69) | |
Cash per Share |
2.30 | 2.16 | 5.12 | 5.28 | |
Shareholders Equity per Share |
3.80 | 0.82 | 1.10 | 1.35 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.80 | 0.82 | 1.10 | 1.35 | |
Free Cash Flow |
114.20 | 77.10 | (12.30) | (24.10) | |
Working Capital |
110.60 | 112.90 | 172.40 | 206.20 | |
Capital Expenditures |
(15.50) | (20.00) | (10.30) | (10.30) | |
Net Current Asset Value |
(1,173.50) | (1,167.20) | (1,029.50) | (946.80) | |
EV/EBIT |
14.96 | 0.00 | 0.00 | 25.38 | |
Capex to Sales |
0.05 | 0.08 | 0.04 | 0.03 | |
Net Profit Margin |
13.06% | (33.16%) | 23.18% | 11.24% | |
Price to Operating Income |
9.67 | 0.00 | 0.00 | 18.87 | |
| Other line items | |||||
Average Receivables |
179.00 | 129.45 | 157.45 | 174.60 | |
Average Payables |
98.70 | 93.25 | 96.65 | 94.75 | |
Average Inventory |
227.35 | 190.95 | 224.50 | 187.15 | |
Average Assets |
2,022.70 | 1,836.85 | 1,853.15 | 1,707.60 | |
Average Common Equity |
176.30 | 112.45 | 136.75 | 83.80 |
Columns are period end dates